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Trends in Buprenorphine Use and Barriers to Medication-Assisted Recovery
Isi Beach1, Richard Brach1, Carolyn Geraci MS1, Kyle Leonard1, Rose Martin1,
Nikkole Turgeon1, Faith Wilson1,Kayla Donohue MPH2, Mariah McNamara MD, MPH3
University of Vermont Larner College of Medicine1 Chittenden County Opioid Alliance2 University of Vermont Medical Center1,3

Introduction

Discussion

Results

This study explores trends in buprenorphine use and
barriers to medication assisted recovery (MAR) from
opioid use disorder in Chittenden County, Vermont.
The goal of our survey was to provide useful data for
funding, legislation, and knowledge around trends in
buprenorphine use and barriers to MAR.
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Background
Vermont continues to trend upward with opioid-related
fatalities. Since 2015, the number of fentanyl related
overdoses doubled and now exceeds the number of
heroin related overdoses.1 Vermont has seen an eightfold
increase in the need for MAR of opioid use disorder
since 2000.2 Since the initiation of the "Hub and Spoke
Model" in 2014, VT has been able to eliminate the
waitlist for receiving MAR and has increased
the number of MAR providers. However, many people
still report using non-prescribed “street” MAR prior to
entering treatment to avoid withdrawal from opiates.3 As
the climate of buprenorphine use continues to evolve,
our study aims to assess the current trend in
buprenorphine use as well as attitudes and barriers to
accessing MAR.
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Figure 3. Motive for buprenorphine use not prescribed
from a doctor.
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Figure 1. Proportions of methods used by 76 respondents to
obtain buprenorphine.
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“Insurance”
“Having to have ID to pick up
script”
“Rides, buses, housing due to
drug use leads to
homelessness”
“The judgement of others”
“The poor community outlook
or lack of positive things to do
sober”
“Getting take-homes for
vacations, holidays, part-time
jobs, regardless of UA results”
“Having to come in everyday”
"Being honest with yourself
and commit to recovery”
“Really wanting to be sober
vs. Using it as another way to
get high”
“No encouragement to
eventually stop MAR”
“Keeps you hooked on a
substance and then have to
detox from the medication
and people relapse”
“Finding a place to get it”
“Finding a spoke doctor”

Figure 2. Primary barriers to accessing MAR.

The three most common themes in participant responses included
socioeconomic barriers social pressures and stigma, and timeconsumption. Recent literature describes how individual financial
constraints and lack of access to insurance or prescribers have been
shown to reduce adherence to MAR.5 Participants also identified
“restrictive policies” such as mandatory counseling as barriers.
There have been ongoing efforts to expand MAR access, such as
increasing numbers of practitioners prescribing MAR and efforts to
reduce the cost of the medication.5 However, current perceptions of MAR
has led to restrictive policies against buprenorphine use in many sober
living facilities in the local community. Many respondents reported
uncertainty regarding adverse effects and the eventual need for
detoxification from MAR. Some logistical concerns also became evident
from our survey, including the long length of prescription and confusion
about where to obtain one. Finding authorized MAR prescribers has
shown to be a nationwide barrier.6
Evidence-based guidelines for providers to successfully counsel patients
upon initiation of MAR are also lacking.6 There is much opportunity for
expansion on this front: in 2018, an app designed to share information
and testimonies about MAR increased interest among some adults with
opioid use disorder.7 This app and similar innovations can benefit patients
interested in receiving MAR by removing some of the barriers to access.
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Methods
Surveys were administered and voluntarily completed in
Chittenden County at institutions that provide services
related safer drug use and/or recovery from substance
use disorders. Inclusion criteria were 18 years of age or
older and history of opioid use without a doctor's
prescription or differently than how they were
prescribed.
The surveys asked about buprenorphine use and barriers
to MAR. Questions regarding buprenorphine use
included history of use, source of acquisition, reason for
use, and barriers to obtaining a buprenorphine
prescription. Questions regarding MAR included
reported interest or current engagement in MAR, a
qualitative question inquiring where respondents would
go to seek MAR, and a qualitative question asking
respondents to describe what they perceive to be the
most significant barriers to being successful with MAR.
Data was analyzed using a mixed-methods approach.
Multiple choice questions were analyzed based on
proportion of answers for each question. Free-response
questions were analyzed based on grounded theory and
sorted into six categories.4
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Figure. 4 Noted barriers to MAR of individuals using
buprenorphine not prescribed from a doctor.
For Recovery/Self-Medicate
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• A significant population of current or prior users/misusers of opioids
are using buprenorphine, indicating an interest in MAR that goes
beyond the treatment currently being accessed within the context of
a healthcare system.
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• Several barriers exist to receiving MAR through a doctor’s
prescription, especially socioeconomic factors and social pressures.
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Figure 5. Motive for buprenorphine use prescribed from
a doctor.
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Figure 6. Noted barriers to MAR of individuals using
buprenorphine prescribed from a doctor.

• Actionable changes include reducing the number of appointments
needed to obtain daily buprenorphine treatment, providing the
community with information on where a prescription can be
obtained, and increasing confidentiality at the clinics themselves.
Solutions for homeless patients seeking MAR should also be
considered.
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